论文部分内容阅读
目的探讨多西他赛联合奥沙利铂,替吉奥化疗方案用于晚期胃癌转化治疗的有效性。方法56例晚期胃癌患者,28例采取术前多西他赛联合奥沙利铂,替吉奥的转化治疗方案;28例直接进行手术。使用单因素及多因素统计学方法分析两组患者的临床病理特征(年龄,性别,T,N,M分期,临床分期,大体分型,组织学分型,分化程度)及R0切除率。结果术前化疗组和直接手术组患者的年龄[(55.82±12.80)岁比(61.54±11.30)岁],性别[(男19例,女9例)比(男23例,女5例)],T分期[(T3 11例,T4 17例)比(T3 7例,T4 21例)],N分期[(N1 25例,N2 3例)比(N1 26例,N2 2例)],M分期[(M0 3例,M0 25例)比(M0 1例,M1 27例)],临床分期[(Ⅲ期3例,Ⅳ期25例)比(Ⅲ期1例,Ⅳ期27例)],大体分型[(溃疡型26例,隆起型2例)比(溃疡型22例,隆起型6例)],组织学分型[(腺癌24例,印戒细胞癌4例)比(腺癌27例,印戒细胞癌1例)],分化程度[(中分化5例,低分化23例)比(中分化8例,低分化28例)]比较,差异均无统计学意义(P>0.05);R0切除率两组比较,差异有统计学意义(53.6%vs 10.7%,P=0.001),单因素及多因素Logistic回归显示术前化疗有助于提高晚期胃癌患者R0切除率(OR:9.615,95%CI:2.349~39.351,P=0.002)。结论多西他赛联合奥沙利铂,替吉奥术前化疗方案提高了晚期胃癌患者的R0切除率。
Objective To investigate the efficacy of docetaxel plus oxaliplatin in the treatment of advanced gastric cancer (GCT). Methods 56 cases of advanced gastric cancer patients, 28 patients preoperative docetaxel combined with oxaliplatin, for the treatment of conversion of Gio; 28 cases were directly underwent surgery. The clinical and pathological characteristics (age, sex, T, N, M staging, clinical stage, general classification, histological classification, differentiation degree) and R0 resection rate were analyzed by univariate and multivariate statistical methods. Results The age (55.82 ± 12.80) years (61.54 ± 11.30) years of age in the preoperative chemotherapy group and the direct surgery group were significantly higher than those in the preoperative chemotherapy group (19 males and 9 females) (23 males and 5 females) , T stage (T3 11 cases, T4 17 cases) (T3 7 cases, T4 21 cases), N stage (N1 25 cases, N2 3 cases) (N1 26 cases, N2 2 cases)], M The clinical stage (3 cases of stage Ⅲ, 25 cases of stage Ⅳ) (1 case of stage Ⅲ, 27 cases of stage Ⅳ) was significantly higher than that of stage (M0 3 cases, M0 25 cases) (M0 1 case, M1 27 cases) (26 cases of ulcer and 2 cases of protuberance) than histological type (24 cases of adenocarcinoma and 4 cases of signet-ring cell carcinoma) than that of adenocarcinoma (22 cases of ulcer and 6 cases of protuberance) 27 cases of cancer and 1 case of signet-ring cell carcinoma). There was no significant difference in the degree of differentiation (5 cases of moderately differentiated and 23 cases of poorly differentiated) (8 cases of moderately differentiated and 28 cases of poorly differentiated) (P > 0.05). R0 resection rate was significantly different between the two groups (53.6% vs 10.7%, P = 0.001). Univariate and multivariate Logistic regression showed that preoperative chemotherapy could improve R0 resection rate in patients with advanced gastric cancer OR: 9.615, 95% CI: 2.349-39.351, P = 0.002). Conclusion Docetaxel combined with oxaliplatin, TIGO preoperative chemotherapy regimen increased R0 resection rate in patients with advanced gastric cancer.